About Neovacs
Neovacs is a company based in Paris (France) founded in 1993. Neovacs has raised $17.91 million across 10 funding rounds from investors including Debiopharm, Kepler Cheuvreux and Maxim Group. Neovacs offers products and services including Kinoide. Neovacs operates in a competitive market with competitors including Biological E, Altimmune, Vaxart, Allergy Therapeutics and Medicago, among others.
- Headquarter Paris, France
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$17.91 M (USD)
in 10 rounds
-
Latest Funding Round
$2.56 M (USD), Post-IPO
Dec 08, 2018
-
Investors
Debiopharm
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Neovacs
Neovacs offers a comprehensive portfolio of products and services, including Kinoide.
Technology for immunotherapy targeting lupus and allergies.
People of Neovacs
Unlock access to complete
Unlock access to complete
Funding Insights of Neovacs
Neovacs has successfully raised a total of $17.91M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2.56 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Neovacs
Neovacs has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Debiopharm, Kepler Cheuvreux and Maxim Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Truffle Capital is recognized as a leading European venture capital firm.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investments are made in innovative life science companies globally.
|
Locked | Locked | Locked |
Investor details for Neovacs
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Neovacs
Investment portfolio details for Neovacs
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Neovacs
Detailed financials for Neovacs
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neovacs Comparisons
Peer comparison for Neovacs
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Neovacs
Neovacs operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological E, Altimmune, Vaxart, Allergy Therapeutics and Medicago, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for treating multiple infectious diseases
|
|
| Locked | Locked | Locked |
Aluminum-free allergy vaccines and diagnostics are developed for treatment.
|
|
| Locked | Locked | Locked |
Developer of vaccines to treat pandemic and seasonal influenza
|
|
| Locked | Locked | Locked |
Developer of vaccines for the treatment of infectious diseases
|
Detailed competitors of Neovacs
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neovacs
Complete news archive for Neovacs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neovacs
Neovacs was founded in 1993 and raised its 1st funding round 14 years after it was founded.
Neovacs is headquartered in Paris, France.
Hugo Brugiere is the current CEO of Neovacs.
Neovacs is a funded company, having raised a total of $17.91M across 10 funding rounds to date.
Neovacs was established in 1993 in Paris, France, as a contract development and manufacturing organization in the biotechnology sector. Vaccine production processes are handled, including formulation and scaling for clinical and commercial needs. Operations are centered in Europe, with expertise applied to various vaccine types. Leadership is provided by CEO Hugo Brugiere, overseeing facilities compliant with regulatory standards.
Neovacs's top competitors include Biological E, Vaxart and Allergy Therapeutics.
Neovacs offers Kinoide.
Neovacs has 6 investors. Key investors include Debiopharm, Kepler Cheuvreux, Maxim Group, Truffle Capital, and APICAP.